Pepti review

What it is

A peptide-led telehealth platform with an unusually broad catalog spanning recovery, weight loss, hormones, longevity, cognition, skin and hair, immune support and sexual wellness, plus at-home blood panels and an IV drip service. It is operated by pepti LLC, a Delaware company.

How it works

Async intake reviewed by a physician. Pepti states that every intake is personally reviewed by a board-certified, US-licensed MD or DO and that no nurse practitioners or algorithms make prescribing decisions — a claim most competitors cannot make, and it names the doctors: Dr. Gene Lee, MD (medical director, family medicine, licensed in 26 states) and Dr. Laeeq Butt, MD, MBA (chief medical officer, internal medicine, 15 states). The physicians are independent contractors, and Pepti is explicit that no doctor-patient relationship exists between you and pepti LLC itself. Medications are compounded by independent FDA-registered 503A or 503B pharmacies, which Pepti describes as a category but does not name individually. Prescriptions ship to 36 states in unbranded, tamper-evident packaging with shipping included; blood testing is available in all 50.

Pricing transparency

Flat, published and cash-pay only, with no insurance billing and HSA/FSA eligibility. Recovery: BPC-157 $209/mo, TB-500 $289, the two combined $289, KPV $229, CJC-1295/ipamorelin $239, oral BPC-157 capsules $229, KPV+BPC-157 capsules $289, KLOW blend $299. Longevity: sermorelin and tesamorelin $189 each, epithalon $209, MOTS-c $209, SS-31 (elamipretide) $299, NAD+ injection $179, NAD+ capsules $159, GHK-Cu injection $239, GHK-Cu capsules $159, glutathione $129, methylene blue $109, 5-Amino-1MQ $159. Weight loss: injectable semaglutide $99, injectable tirzepatide $199, oral semaglutide $249, oral tirzepatide $399, liraglutide $239, retatrutide $399, AOD-9604 $199, tesofensine $229. Hormones: testosterone cypionate $109, testosterone cream $159, TRT with anastrozole $129, enclomiphene $119, gonadorelin $139, HCG $319. Sexual wellness: tadalafil troche $79, sildenafil troche $179, Trimix $159, PT-141 $189–$219 by route. Blood panels are $199; a hereditary cancer screen is $399. We checked the cheap end specifically — the $99 semaglutide figure is corroborated on two separate surfaces, its category listing and its cost page, where Pepti describes the plan as "flat and transparent at $99/mo all-in."

Branded vs compounded

Compounded, and disclosed properly. Pepti's safety page states that all medications are compounded by independent FDA-registered 503A or 503B pharmacies against an individual prescription, that compounded medications are not FDA-approved as products, that they may not undergo the same testing as commercially manufactured drugs, and that statements about them have not been evaluated by the FDA. It carries a dedicated off-label section explaining that many of its peptides are prescribed off-label and what that means — a disclosure we rarely see spelled out this directly. The catalog nonetheless includes several compounds with no approved reference product in any jurisdiction: retatrutide is an investigational triple agonist still in phase 3, tesofensine has never been approved anywhere, and AOD-9604, SS-31/elamipretide and epithalon are likewise investigational. Compounding an approved drug and compounding a molecule that has never cleared a regulator are different propositions, and the price list does not distinguish between them. On the underlying science, most of this menu rests on preclinical or early human data — BPC-157, TB-500, KPV, MOTS-c, epithalon and GHK-Cu have little to no controlled human outcome evidence, and injected NAD+ has none.

Pros and watch-outs

The evidence behind what Pepti prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• BPC-157 dosage and safety: why there is no validated human dose

  The honest answer to a heavily-searched query: no established human dose, no dose-ranging trial, no approval, and no long-term safety data. Here is why.

• TB-500 and thymosin beta-4: separating the trials from the hype

  Real Phase 2 dry-eye data, deep preclinical neuro/cardiac work, and a recovery-market use that was never actually tested.

• KPV peptide: what the evidence actually shows (benefits, dosage talk, and side effects)

  KPV is the anti-inflammatory tripeptide tail of α-MSH, sold for gut, inflammation, wound-healing and skin. The mechanism is real and the mouse data are real — but there are essentially no human trials. A straight read of where the science stands.

• CJC-1295 & ipamorelin dosage: the circulated numbers vs. what's actually proven

  There's no FDA-approved dose for either peptide. We explain the pharmacology behind the microgram figures people circulate — the saturation-dose idea, the timing, the stack logic — and why none of it is clinically validated.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence

  A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.

• Epitalon (epithalon): the honest evidence behind the telomerase and longevity claims

  Marketed for telomerase activation and life extension. The supporting science is old, small, and almost entirely from one Russian lab — and largely unreplicated.

• MOTS-c: real mitochondrial biology, absent human evidence

  A genuine mitochondrial-derived peptide with interesting rodent data on metabolism and exercise — but no human outcome trials. Promising biology, not a proven therapeutic.

• SS-31 (elamipretide): an elegant mitochondrial mechanism meets a hard clinical record

  A cardiolipin-binding peptide with a beautiful mechanism and a mostly disappointing trial history — including a failed myopathy trial and a narrow, confirmation-pending Barth syndrome approval. A straight read.

• GHK-Cu: the copper peptide between real skincare and overclaim

  A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• Methylene blue: the longevity 'biohack' that's actually a drug

  Low-dose methylene blue has a plausible mitochondrial mechanism and a real single-dose memory signal — but it's an FDA-approved drug, not a supplement, its anti-aging claims are preclinical, and it can cause fatal serotonin syndrome with antidepressants.

• 5-Amino-1MQ: an elegant mechanism with no human trials

  An NNMT inhibitor that reverses obesity in mice by sparing the NAD+ pool — without reducing food intake. The mechanism is plausible; the human evidence is nonexistent.

• AOD-9604: the “anti-obesity drug” peptide that failed its own trials

  A synthetic growth-hormone tail fragment built to burn fat. Its mechanism is real and its safety was clean — but the pivotal human obesity trial showed no significant weight loss versus placebo, and the program was discontinued.

• Tesofensine: the striking weight-loss number with a big asterisk

  A triple monoamine reuptake inhibitor repurposed from a failed Alzheimer's drug. Its ~9.2% Phase II weight loss is real but flagged — a Lancet Expression of Concern, a completed Mexico Phase III that was never peer-reviewed or turned into approval, and still no FDA approval.

• Retatrutide: the triple agonist and what its Phase 2 data actually show

  A single peptide hitting GIP, GLP-1 and glucagon produced the largest weight-loss numbers yet reported — in Phase 2. A straight read of the evidence and its limits.

• What the semaglutide weight-loss trials actually showed

  STEP 1, STEP 4, and SELECT — the efficacy, the rebound, and the cardiovascular signal, read straight from the primary literature.

• TRT: what testosterone therapy is actually proven to do

  An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.

• Enclomiphene: the evidence for restoring testosterone without replacing it

  Randomized trials, including two Phase III RCTs, show enclomiphene restores a man's own testosterone while preserving fertility — but it was never FDA-approved.

• PT-141 (bremelanotide): the evidence on a peptide that is actually FDA-approved

  Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.

• Kisspeptin: real reproductive-axis science, unproven as a sold therapy

  A genuine human hormone atop the testosterone axis, with serious early human research — but the marketed libido and T-booster products are off-label extrapolations at unestablished doses.

How Pepti compares

A few alternatives worth a look, depending on what you’re optimizing for.

• Rehydra+ Wellness

  Buyers who want a low entry dose and accept the price rising as they titrate

  See Rehydra+ Wellness →
• the edit.

  Buyers who want the practice, pharmacy and management company all named before they pay

  See the edit. →
• AurenRx

  Buyers who want a named pharmacy and will read past the advertised headline price

  See AurenRx →